Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of SK-1011 in Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
jRCT2080221648Phase 2
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in age-related macular degeneration (AMD) and Subretinal neovascularization comparing SK-1011 60 mg BID with Placebo BID (2 arms).
02
Drugs
SK-1011
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on jRCT2080221648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221648.